TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03112512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optimal PEEP guided by EIT
Description: Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optimal PEEP guided by G5 ventilator
Description: Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
Study: NCT02627547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal training
Description: 5-10 hours of endurance training each week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De-training
Description: No training
Study: NCT02017392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Lidocaine Cream
Description: Compound Lidocaine Cream ,1-2 grams per person.
Study: NCT02047591

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxing-touch method
Study: NCT01192269

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA (docosahexaenoic acid)
Description: 1 x 950 mg capsules per day orally, each capsule providing \~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
Study: NCT01670786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurodesis
Description: Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pleurodesis
Description: Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
Study: NCT02511834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEST External Support

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Artery Bypass Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Surgery
Study: NCT01097642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be given at 400mg/m\^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m\^2 IV over 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone will be given at 40mg/m\^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
Study: NCT02761187

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT01796119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ridge Splitting
Description: To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implants placed using drilling technique
Description: To measure the horizontal bone width before and after implant insertion and 6 months post-op.~To measure BLI measured using PA radiographs taken immediately and 6 months post-op.~To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.~To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length.
Study: NCT03241823

Intervention type: DIAGNOSTIC_TEST
Intervention: Abdominal ultrasound .
Description: Abdominal ultrasound for each patient before and after treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Model for End-Stage Liver Disease
Description: Model for End-Stage Liver Disease before and after treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibro Scan.
Description: Liver stiffness by Fibro scan before and after treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: Child-Turcotte-Pugh score.
Description: Child-Turcotte-Pugh score before and after treatment
Study: NCT01984645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Notification
Description: Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
Study: NCT02153424

Intervention type: DRUG
Intervention: Apixaban
Study: NCT00874458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiomammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Study: NCT02080481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infiniti Plus needle guidance system
Description: The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
Study: NCT01928459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGJ398
Description: BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 will be administered orally once daily on each day of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 will be administered orally once daily on each day of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 will be administered orally once daily on each day of the 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 will be administered orally once daily on each day of the 28-day cycle.
Study: NCT01835639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks
Description: Supplements will be provided as oral capsules.
Study: NCT01332175

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provent®
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Provent®
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Provent®
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Provent®
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Nightly use of Provent® versus Placebo-Provent® versus CPAP
Study: NCT00797212

Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo Blood Glucose Monitoring System
Description: Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
Study: NCT03109080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: five levels of dose, per os administration, twice daily each day
Study: NCT02080481

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional block needle
Description: conventional block needle used for insertion of femoral nerve catheters.
Study: NCT02345772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant 500 mg
Description: Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
Study: NCT03109080

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: 3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
Study: NCT04620200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg
Study: NCT03615612

Intervention type: OTHER
Group type: OTHER
Intervention: QuickSee refractive error assessment + glasses
Description: QuickSee refractive error assessment + glasses

Intervention type: OTHER
Group type: OTHER
Intervention: QuickSee refractive error assessment + glasses
Description: QuickSee refractive error assessment + glasses
Study: NCT00640159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zelapar
Description: Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
Study: NCT00463229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interprofessional Team Approach
Description: Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
Study: NCT00982436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin
Description: Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 70 Gy in 35 fractions to gross tumor and lymph node metastases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 1.5 intravenous weekly during radiotherapy
Study: NCT00210275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Educational Message
Description: Three forms of printed educational materials (short or long educational messages and patient reminder notes)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Educational Message
Description: Three forms of printed educational materials (short or long educational messages and patient reminder notes)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Printed Educational Message
Description: Three forms of printed educational materials (short or long educational messages and patient reminder notes)
Study: NCT04478487

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medolac human milk based human milk fortifier (MHMHMF)
Description: MHMHMF is admixed with expressed or donor human milk in graded doses according to tolerated feed volume according to established guidelines and maintain adequate micronutrient levels.
Study: NCT01515241

Intervention type: DRUG
Group type: OTHER
Intervention: CER-001
Description: Weekly injection
Study: NCT02404441

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PDR001
Description: anti-PD1 antibody

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PDR001
Description: anti-PD1 antibody
Study: NCT03387254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR + active brain stimulation
Description: Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: VR + sham brain stimulation
Description: Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)
Study: NCT02238041

Intervention type: DEVICE
Intervention: GlucoClear System
Study: NCT03205566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400Mg Tab
Description: bd for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir 400Mg Tab
Description: bd for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine 150Mg Tablet
Description: + Raltegravir 400Mg tablet bd for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamivudine 150Mg Tablet
Description: + Raltegravir 400Mg tablet bd for 7 days
Study: NCT02345772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab (H, 8mg/kg
Description: Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
Study: NCT04240002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: Administered by intravenous (IV) infusion
Study: NCT02345772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab (P, 840 mg
Description: Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
Study: NCT02817113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
Study: NCT02984241

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Coping Skills Training
Description: Access to a specialized coping skills training website

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Coping Skills Training
Description: Access to a specialized coping skills training website

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Usual Web Care
Description: Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coach Support
Description: Access to a professional coach by phone
Study: NCT02306863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vibrating chair
Description: vibration provided via physioacoustic method

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham treatment
Description: simulated whole-body vibration
Study: NCT00898300

Intervention type: OTHER
Intervention: biologic sample preservation procedure

Intervention type: PROCEDURE
Intervention: biopsy
Study: NCT04373408

Intervention type: PROCEDURE
Intervention: ACL repair without anterolateral repair
Description: Surgical repair of the ACL using semitendinous autograft

Intervention type: PROCEDURE
Intervention: ACL repair with anterolateral repair
Description: Surgical repair of the ACL using semitendinous autograft, and surgical repair of the ALL using an allograft (Arthrex, Extra-Articular Augmentation device)
Study: NCT02214225

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine (QIV)
Description: One 0.5 mL intramuscular dose into the deltoid muscle

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine (TIV-1)
Description: One 0.5 mL intramuscular dose into the deltoid muscle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Influenza Vaccine (TIV-2)
Description: One 0.5 mL intramuscular dose into the deltoid muscle.
Study: NCT01673815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video (played on a computer monitor)
Description: The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video (played on a computer monitor)
Description: The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video (played on a computer monitor)
Description: The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video (played on a computer monitor)
Description: The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
Study: NCT04240002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Administered by intravenous (IV) infusion
Study: NCT03029078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal microbiota transplant
Description: We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
Study: NCT02938078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avenova Lid Cleanser
Description: Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
Study: NCT01792375

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent membrane sweeping with Dinoprostone
Description: Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg Dinoprostone vaginal insert
Description: For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening
Study: NCT02520258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT)
Description: OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Description: OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet soda containing aspartame only
Description: 7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
Study: NCT00621556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1068 (Synthetic Human Secretin)
Description: Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
Study: NCT01375803

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel dietary fiber
Description: oral consumption in beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel dietary fiber
Description: Oral consumption in beverage

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral consumption in beverage
Study: NCT03603899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hp 129Xenon
Description: 129 Xenon is a noble gas with no taste or smell. It will be made slightly magnetic (also called hyperpolarizing) and then inhaled into the lungs to provide better pictures of the lungs during MRI.
Study: NCT03840772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Treatment with eribulin
Study: NCT02891148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 690517
Study: NCT00686985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, docetaxel
Description: Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks